The Technical Analyst
IsoRay Inc [ISR]
Exchange: AMEX Industry: Medical Instruments & Supplies
IsoRay Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.384
America/New_York / 17 feb 2023 @ 16:00
| RATING 2023-03-30 |
|---|
| B+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 351.26 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.363 - 0.405 ( +/- 5.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-21 | Williamson Robert F Iii | Buy | 3 663 | Common Stock |
| 2023-12-18 | Hunt Jonathan Robert | Buy | 125 000 | Common Stock |
| 2023-12-19 | Williamson Robert F Iii | Buy | 13 680 | Common Stock |
| 2023-12-18 | Williamson Robert F Iii | Buy | 10 000 | Common Stock |
| 2023-12-19 | Puhlmann Markus | Buy | 400 000 | Common Stock |
| INSIDER POWER |
|---|
| 38.27 |
| Last 96 transactions |
| Buy: 20 677 783 | Sell: 10 913 801 |
Forecast:
01:40 - $0.335
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.384 (0.00% ) |
| Volume | 0.145 mill |
| Avg. Vol. | 0.281 mill |
| % of Avg. Vol | 51.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ISR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ISR
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Latest Press Releases
2022-10-31 08:14:00 - Press Release
Isoray To Announce First Quarter Fiscal 2023 Financial Results On November 10, 2022
Conference call is thursday, november 10, 2022 at 4:30 p.m. et/1:30 p.m. pt conference call is thursday, november 10, 2022 at 4:30 p.m. et/1:30 p.m. pt
2022-10-18 16:30:00 - Press Release
Isoray Medical, Inc. And Viewpoint Molecular Targeting, Inc. Announce Investor Webcast On October 19, 2022 At 4:15 P.m. Edt
Richland, wash. & coralville, iowa--(business wire)--isoray, inc. (nyse american: isr), a medical technology company and innovator in seed brachytherapy, and viewpoint molecular targeting, inc., a radiopharmaceutical company developing precision lead-212-based Α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced they will hold an investor webcast wednesday, october 19, 2022, at 4:15 p.m. edt. the presentation will provide an overview of viewpoint’s pipeline along with a review of data presented at this year’s european association of nuclear medicine conference which concludes on october 19 in barcelona, spain. speakers on the call will include isoray ceo lori woods, viewpoint molecular targeting ceo thijs spoor, viewpoint molecular targeting cso and co-founder michael k...
2022-09-21 08:13:00 - Press Release
Isoray To Announce Fourth Quarter And Fiscal Year End 2022 Financial Results On September 28, 2022
Conference call is wednesday, september 28 at 4:30 p.m. et/1:30 p.m. pt conference call is wednesday, september 28 at 4:30 p.m. et/1:30 p.m. pt
2022-04-29 08:05:00 - Press Release
Isoray To Announce Third Quarter Fiscal 2022 Financial Results On May 10, 2022
Conference call is tuesday, may 10, 2022 at 4:30 p.m. et/1:30 p.m. pt conference call is tuesday, may 10, 2022 at 4:30 p.m. et/1:30 p.m. pt
2022-01-26 08:10:00 - Press Release
Isoray To Announce Second Quarter Fiscal 2022 Financial Results On February 8, 2022
Conference call is tuesday, february 8, 2022 at 4:30 p.m. et/1:30 p.m. pt conference call is tuesday, february 8, 2022 at 4:30 p.m. et/1:30 p.m. pt
Latest News
2023-02-16 18:49:30 - Zacks Investment Research
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-10 18:55:05 - Seeking Alpha
Isoray, Inc. (ISR) Q1 2023 Earnings Call Transcript
Isoray, Inc. (NYSE:ISR ) Q1 2023 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular Targeting Jonathan Hunt - CFO Conference Call Participants Mike Ott - Oppenheimer Operator Good day, ladies and gentlemen. And welcome to the Isoray, Inc. Q1 FY 2023 Call.
2022-10-31 08:14:00 - GlobeNewsWire
Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT
2022-10-18 16:30:00 - Business Wire
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
2022-09-28 22:35:23 - Seeking Alpha
Isoray, Inc. (ISR) Q4 2022 Earnings Call Transcript
Isoray, Inc. (NYSE:ISR ) Q4 2022 Earnings Conference Call September 28, 2022 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Thijs Spoor - Chief Executive Officer, Viewpoint Molecular Targeting Jonathan Hunt - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Mike Ott - Oppenheimer Operator Good afternoon, ladies and gentlemen. And welcome to the Isoray, Inc. Fourth Quarter Fiscal Year 2022 Call.
2022-09-28 18:49:25 - Zacks Investment Research
IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-09-21 08:13:00 - GlobeNewsWire
Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022
Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT
2022-04-29 08:05:00 - GlobeNewsWire
Isoray To Announce Third Quarter Fiscal 2022 Financial Results on May 10, 2022
Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, May 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT
2022-02-08 20:45:05 - Seeking Alpha
Isoray, Inc. (ISR) CEO Lori Woods on Q2 2022 Results - Earnings Call Transcript
2022-02-08 19:59:06 - Zacks Investment Research
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 8.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?